24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Diabetes
Resources
Basic InformationLatest News
FDA Testing Levels of Carcinogen in Diabetes Drug MetforminMom-to-Be's Diabetes May Up Odds of Heart Disease in Her KidsPrediabetes Now Common Among Teens, Young AdultsHeart Attack at 44 Helped Her Realize Diabetes' DangersDiabetes Tougher on Women's HeartsDiabetes Technology Often Priced Out of ReachSupplements Don't Prevent Kidney Disease in Type 2 DiabeticsWhy Are Insulin Prices Still So High for U.S. Patients?Health Tip: Snacks for People With DiabetesHigh-Tech Pacifier Might Monitor Baby's Blood SugarThe Exercise Effect and PrediabetesNext-Gen Artificial Pancreas Boosts Blood Sugar ControlHurricanes Raise Death Risk for Older Diabetics, Even Years LaterYou've Lost the Weight -- Now Keep It Off to Keep Diabetes at BayCould a Pill Replace Insulin Shots?High-Fiber Diet Tied to Lower Heart Risk in Diabetes PatientsJust a Little Weight Loss Can Put Diabetes Into RemissionAffordable Care Act Insured Millions of Uninsured DiabeticsOlder Diabetics May Be Getting Too Much InsulinIt Takes Less Weight to Trigger Diabetes in Minorities Than WhitesFDA OKs New Pill for Type 2 DiabetesAHA News: These Diets Helped Women With Diabetes Cut Heart Attack, Stroke RiskKeeping Blood Sugar Steady Helps You Live Longer With DiabetesAre Shorter Folks at Higher Risk for Type 2 Diabetes?Diabetes Control Has Stalled Across U.S.Fish Oil Not a Magic Pill Against DiabetesAsian Study Finds Diabetes, Heart Failure a Dangerous DuoCaring Doctors Can Be Life-Changing for Diabetic PatientsKeto Diet May Help Control Type 2 DiabetesHealth Tip: Living With HypoglycemiaHealth Tip: Understanding PrediabetesFDA Approves First Needle-Free 'Rescue' Drug for Low Blood Sugar EpisodesDiabetes Raises Heart Failure Risk More in Women Than MenCan You Live Well With Type 1 Diabetes for 81 Years? Just Ask Don RayEasing Depression Can Bring Longer Life to People With DiabetesMedtronic Recalls Some Insulin Pumps as FDA Warns They Could Be HackedFDA Approves Victoza Injection for Children 10 Years and OlderCommon Infant Vaccine May Also Shield Kids From Type 1 DiabetesType 1 Diabetes Might Affect Young Kids' Brain DevelopmentDrug May Help Delay Onset of Type 1 DiabetesVitamin D Supplements Don't Prevent Type 2 Diabetes: StudyWhat and How You Eat Affects Your Odds for Type 2 DiabetesAHA News: Diabetes and Heart Failure Are Linked; Treatment Should Be TooMidlife Diabetes Can Really Raise Your Odds for Stroke Years LaterTight Diabetes Control Alone May Not Benefit the Heart Long-TermOpen Communication Helps Teens Manage Type 1 DiabetesNew Gene Variants for Type 2 Diabetes FoundPost-Hospital Low Blood Sugar a Danger to DiabeticsAHA News: Why Are Women With Diabetes at Greater Risk for Poor Heart Health?Newer Diabetes Drugs Linked to 'Flesh-Eating' Genital Infection
Links
Related Topics

Medical Disorders

Common Diabetes Drug May Also Shield Kidneys, Heart

HealthDay News
by -- Robert Preidt
Updated: Apr 15th 2019

new article illustration

MONDAY, April 15, 2019 (HealthDay News) -- A common diabetes drug may also greatly reduce the odds for death from kidney failure and heart disease in diabetes patients with kidney disease, a new study finds.

The news on Invokana (canagliflozin) is important, experts say, because diabetes and kidney trouble so often go together.

"Diabetes is the leading cause of kidney failure worldwide, but for almost two decades there have been no new treatments to protect kidney function," noted study lead author Vlado Perkovic. He's a professor at The George Institute for Global Health at Oxford University in the United Kingdom.

"This definitive trial result is a major medical breakthrough as people with diabetes and kidney disease are at extremely high risk of kidney failure, heart attack, stroke and death," Perkovic said in a university news release. "We now have a very effective way to reduce this risk using a once daily pill."

The research was paid for by drug company Janssen, which makes Invokana. The study involved more than 4,400 patients with diabetes and kidney disease across 34 countries. Half took Invokana and half took a "dummy" placebo pill. All of them received care for kidney disease according to current guidelines.

Those who took Invokana had a 30% lower risk of developing kidney failure, a 30% lower risk of dying from kidney failure or heart disease, a 20% lower risk of major heart events such as heart attack, stroke, or heart-related death, and a 39% lower risk of hospitalization for heart failure, the researchers reported.

The findings were published April 15 in the New England Journal of Medicine.

There was no higher risk of major side effects among those who took Invokana, according to the study, which was also due to be presented Monday at the ISN World Congress of Nephrology, in Melbourne, Australia.

Invokana is from a class of diabetes medicines known as sodium glucose transporter 2 (SGLT2) inhibitors.

Study co-author Meg Jardine, associate professor at The George Institute, said, "With 5 million people worldwide predicted to have kidney failure by 2035, this is a major breakthrough."

Two experts in diabetes and renal (kidney) care who read over the new study agreed the findings are significant.

"Upwards of 40% of end-stage renal disease patients have diabetes as the cause of their renal failure," noted Dr. Maria DeVita, chief of nephrology at Lenox Hill Hospital in New York City.

She explained that SGLT2 inhibitor medicines like Invokana work by blocking the "reuptake" of glucose within the kidney. More of this blood sugar, as well as salt, are therefore excreted harmlessly in urine instead of lingering in the kidneys where they can do damage, DeVita said.

So, Invokana "may substantially change the trajectory of kidney decline, preserving kidney function for years longer than we thought possible for the long term," DeVita said. "This is wonderful news for those with diabetic kidney disease."

Dr. Guy Mintz directs cardiovascular health at the Sandra Atlas Bass Heart Hospital in Manhasset, N.Y. He also believes the new findings are "exciting."

"With another impressive study of this family of medications, SGLT2 inhibitors should now be utilized in all type 2 diabetic patients with kidney disease and increased cardiovascular risk," as long as there are no reasons not to do so, Mintz believes.

"This is another tool in our belt to reduce progressive kidney disease and cardiac events in our type 2 diabetic population with kidney disease," he said.

More information

The National Kidney Foundation has more on diabetes and kidney disease.